(S028) Patient-Level DNA Damage and Repair Pathway Profiles Are Prognostic After Prostatectomy for High-Risk Prostate Cancer

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Patient-level DDR pathway profiling revealed distinct clusters. Individual DDR pathways and a composite biomarker showed strong prognostic performance with the long-term outcomes of metastatic progression and OS, which may be useful for risk stratification of high-risk prostate cancer patients aged < 70 years.

Joseph R. Evans, MD, PhD, Shuang Zhao, MSE, Scott A. Tomlins, MD, PhD, Karen E. Knudsen, PhD, Eric A. Klein, MD, Robert B. Den, MD, R. Jeffrey Karnes, MD, Elai Davivioni, PhD, Felix Y. Feng, MD; University of Michigan; Thomas Jefferson University; Cleveland Clinic; Mayo Clinic; GenomeDx Biosciences Inc.

PURPOSE/OBJECTIVES: A substantial number of patients who are diagnosed with high-risk prostate cancer are at risk for metastatic progression after primary treatment. Better biomarkers are needed to identify patients who are at the highest risk so that therapy can be intensified. 

MATERIALS AND METHODS: We developed a novel patient-level DNA damage and repair (DDR) pathway profiling approach in a cohort of 1,090 patients undergoing prostatectomy for high-risk prostate cancer who had long follow-up (mean, 7–13 yr). High-density microarray gene expression data from prostatectomy samples were analyzed for DDR pathway enrichment with the gene set enrichment analysis algorithm and clustered hierarchically. The prognostic performance of pathway-based biomarkers for metastatic progression and overall survival (OS) was analyzed with univariate and multivariate logistic regression models. 

RESULTS: We found that there were distinct clusters of DDR pathway patterns within the cohort. DDR pathway enrichment correlated only weakly with the clinical variables age, Gleason score, and PSA (Spearman’s rho ≤ 0.20) and correlated much more strongly with AR pathway enrichment (Spearman’s rho up to 0.82). Many of the individual pathways were significantly associated with increased metastatic progression risk (odds ratio [OR] = 1.28–1.78) and worse OS (OR = 1.51–2.23) on univariate and multivariate analysis, and a composite DDR pathway biomarker showed improved prognostic performance for metastatic progression risk (OR = 2.09 [1.33, 3.28]). Interestingly, this prognostic significance was restricted to patients aged < 70 years. 

CONCLUSIONS: Patient-level DDR pathway profiling revealed distinct clusters. Individual DDR pathways and a composite biomarker showed strong prognostic performance with the long-term outcomes of metastatic progression and OS, which may be useful for risk stratification of high-risk prostate cancer patients aged < 70 years.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Related Content